Separate names with a comma.
DFTX Russell Reconstitution Update Some people may see the MarketScreener headlines saying Definium Therapeutics was “dropped” from the Russell...
Definium Therapeutics’ Emerge Phase 3 readout looks like a major inflection point for DT120 ODT. The headline is simple: one supervised 100 µg...
Post Phase 3 Results and Raise Clarity I think this week may end up being one of the most important moments the psychedelic medicine sector has...
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive...
Better Sex, Better Hair, Better Sleep: ‘Humanmaxxing’ Is Here - New York Times...
Sekur Private Data Ltd. Announces Non-Brokered Private Placement...
Drugs that change your mind are about to hit the market https://www.linkedin.com/pulse/drugs-change-your-mind-hit-market-steven-dickman-v5t3e/...
S.4220 - Veterans Health Administration Novel Therapeutics Preparedness Act https://www.congress.gov/bill/119th-congress/senate-bill/4220/text
Why Trump is pushing psychedelics research to treat mental illness...
ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS...
Compass Pathways — Quick Backstory / Key Points Compass Pathways is a clinical-stage biotech company focused on mental health treatments. Its...
Where Psychedelic Treatments Fit in Modern Clinical Care PAT as specialty care, not a replacement for ongoing therapies....
DT-120 for Generalized Anxiety: Addressing the Gap With Optimized LSD Pharmacotherapy Author(s)Jessica Malberg, PhD, Daniel R. Karlin, MD, MA...
